QingHe Biotech

QingHe Biotech is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of innovative antibody-based therapies for cancer. The company's core strength lies in its proprietary Masking technology platform, which enables the creation of conditionally active biologics that are specifically triggered within the tumor microenvironment. By masking the antigen-binding domain of antibodies with a peptide shield that is only removed by tumor-associated proteases, QingHe Biotech aims to minimize off-target toxicities and expand the therapeutic window of potent immune checkpoints. Its lead candidate, QH-101, is a masked PD-L1 antibody currently in Phase 2 clinical trials, demonstrating the platform's potential to improve safety over traditional inhibitors. The company's pipeline also includes masked versions of CTLA-4, CD47, and 4-1BB, targeting a wide range of solid and hematological malignancies.